Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06506513 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Targeting the Skeletal Muscle to Treat Metabolic Dysfunction-associated Steatotic Liver Disease

Study acronym: MYO-MASLD
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Primary completion date: Oct 2025 to Sep 2027
    • Start date changed from estimate of Oct 2024 to Sep 1, 2025
    • Study completion date: Sep 2026 to Sep 2027
    • Site details revised at 2 of 2 sites
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Muscle changes including myosteatosis are reported as highly prevalent in metabolic dysfunction-associated steatotic liver disease (MASLD). Recent studies highlighted a link between muscle fat content and liver disease severity. Conversely, MASLD histological remission though diet or metabolic surgeries is also linked to a decrease in muscle fat content. Therefore, skeletal muscle appears as a potential target to treat MASLD.
Trial Details
NCT Number NCT06506513
Lead Sponsor Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Collaborators: Concerted Research Action, Fonds National de la Recherche Scientifique
Conditions
(from sponsor)		 Metabolic Dysfunction-associated Steatotic Liver Disease
Related terms Motor Activity
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov